Fingolimod (Gilenya): Warning about rare cases of progressive multifocal leukoencephalopathy (PML)

Last Updated on

August 06, 1015 – The American Food and Drug Administration (FDA) has just issued a warning that a case of definite progressive multifocal leukoencephalopathy (PML) and a case of probable PML have been reported in patients taking Fingolimod (Gilenya) for multiple sclerosis (MS). These are the first cases of PML reported in patients taking Fingolimod (Gilenya) who had not been previously treated with an immunosuppressant drug for MS or any other medical condition. As a result, information about these recent cases is being added to the newest and updated version of the Fingolimod (Gilenya) drug label.

OML IBackground: Fingolimod (Gilenya) is an immunomodulator shown to benefit patients with relapsing forms of MS.  This type of MS causes attacks or relapses, which are periods of time when symptoms get worse.  Immunomodulators alter the immune system to reduce inflammation. PML is a rare and serious brain infection caused by the John Cunningham (JC) virus.  The JC virus is a common virus that is harmless in most people but can cause PML in some patients who have weakened immune systems, including those taking immunosuppressant drugs.

In an August 2013 Drug Safety Communication, FDA reported that a patient developed PML after taking Fingolimod (Gilenya). At the time, PML could not be conclusively linked to Fingolimod (Gilenya) in this case because prior to Fingolimod (Gilenya) treatment the patient had been treated with an immunosuppressant drug that also can cause PML and during Fingolimod (Gilenya) treatment the patient had received multiple courses of intravenous corticosteroids, which can weaken the immune system.

Recommendation: Patients taking Fingolimod (Gilenya) should contact their health care professionals right away if they experience symptoms such as new or worsening weakness, increased trouble using their arms or legs, or changes in thinking, eyesight, strength, or balance. Patients should not stop taking Fingolimod (Gilenya) without first discussing it with their health care professionals. Health care professionals should stop Fingolimod (Gilenya) and perform a diagnostic evaluation if PML is suspected. See the Drug Safety Communication for additional recommendations.

Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA’s MedWatch Safety Information and Adverse Event Reporting Program at www.fda.gov/MedWatch/report.

Additional topic information: Since immunodeficiency causes this virus to progress to PML, immunosuppressants are contraindicative to those infected. We should note that in  fact, a number of marketed drugs have been associated with PML with  according action by the FDA as follows: The boxed warning for the drug Rituximab  (Rituxan) includes a statement that JC virus infection resulting in PML and death has been reported in patients treated with the drug. The boxed warning for the drug Natalizumab (Tysabri)  includes a statement that JC virus resulted in progressive multifocal leukoencephalopathy developing in three patients who received natalizumab in clinical trials. The boxed warning was added on Feb. 19, 2009, for the drug Efalizumab (Raptiva) includes a statement that JC virus, resulting in progressive multifocal leukoencephalopathy, developed in three patients who received efalizumab in clinical trials. The drug was pulled off the market because of the association with PML on April 10, 2009. A boxed warning for Brentuximab vedotin (Adcetris) was issued by the FDA on January 13, 2011 after two cases of PML were reported. Lately, risks for the development of PML in some patients taking Dimethyl Fumarate (Tecfidera) and Belatacept (Nulojix) have been discussed as well.

Print Friendly, PDF & Email

Tags: , , , , , , , ,
About the Author
Joseph Gut - thasso Ph.D.; Professor in Pharmacology and Toxicology. Senior expert in theragenomic and personalized medicine and individualized drug safety. Senior expert in pharmaco- and toxicogenetics. Senior expert in human safety of drugs, chemicals, environmental pollutants, and dietary ingredients.

Your opinion

Comment

No comments yet

thasso: conditions

thasso: newest tweets

thasso: recent comments

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • Artificial RNA editing with ADAR for gene therapy July 9, 2020
    Many of the diseases caused by point mutations have no established therapeutic approaches. Prof. Tsukahara and colleagues (Japan Advanced Institute of Science and Technology) are studying a therapeutic method using artificial RNA editing. Artificial site-directed RNA editing is an important technique for modifying genes and ultimately regulating protein function. We are trying to modify the […]
  • Amygdala changes in male patients with schizophrenia and bipolar disorder July 9, 2020
    Researchers at Kumamoto University, Japan have revealed that DNA methylation occurs in the gene that codes serotonin transporter (SERT), a protein that regulates neurotransmitter transmission, in schizophrenia and bipolar patients. Particularly prominent in males and patients with certain genetic polymorphisms, this methylation is inversely correlated with volume of the amygdala in the brain. This work […]
  • Surprisingly many peculiar long introns found in brain genes July 9, 2020
    In a recent study of genes involved in brain functioning, their previously unknown features have been uncovered by bioinformaticians from the Moscow Institute of Physics and Technology and the Institute of Mathematical Problems of Biology, RAS. The findings are reported in PLOS One.
  • Major cause of rare genetic mitochondrial disease identified July 9, 2020
    A cutting-edge study from the Murdoch Children's Research Institute (MCRI) has given hope to families of children born with a fatal heart muscle disease caused by faulty cell machinery.
  • Spatial mapping method pinpoints potential new therapeutic targets in lupus July 8, 2020
    A team of researchers from Children's Hospital of Philadelphia (CHOP) used a new method of pinpointing potential disease-causing changes in the genome to identify two new potential therapeutic targets for lupus, while also paving the way for more accurately identifying disease-causing variations in other autoimmune disorders. The findings were published online in Nature Communications.
  • Lung screening bus brings high-tech health care directly to patients July 14, 2020
    A mobile platform for lung cancer screening with low-dose computed tomography (CT) can be developed with limited financial risk and take powerful screening tests directly to patients, including underserved rural areas where rates of new lung cancer cases tend to be higher.
  • Mismatched caregiver-infant interactions during feeding could boost babies' risk of later obesity July 14, 2020
    A new integrative review examined evidence related to infants' self-regulation of behavior and emotion, and how that relates to interactions when they are fed by their caregivers, including how those interactions may derail infants' ability to regulate their intake of food. The review found that infants who are fed in the absence of hunger or […]
  • When a pandemic strikes, we still expect an ambulance July 14, 2020
    Edith Cowan University (ECU) PhD candidate and paramedic Cameron Anderson investigated community attitudes regarding the professional obligation of paramedics to respond during pandemics.The research showed that, pandemic or not, Australians expected an ambulance to arrive if children were involved, if there was adequate protective equipment and if it involved our immediate families.
  • Age of sexual debut among young gay-identified sexual minority men July 14, 2020
    Young gay sexual minority men - especially Black and Latino youth - have their first sexual experiences at younger ages, emphasizing a need for comprehensive and inclusive sex education, according to Rutgers researchers.
  • COVID-19 pandemic could be learning opportunity for middle-grade students July 14, 2020
    Educators could use the COVID-19 outbreak to help middle-schoolers better understand the world, according to new research from faculty at Binghamton University, State University of New York.
Top